ScinoPharm Taiwan Ltd. offers process research and development and the production of active pharmaceutical ingredients. The Company provides services to pharmaceutical industries globally.

Board Of Directors Approved The Company'S
Consolidated Financial Report Of Q3, 2025

Announcement Of The Expected Board Meeting Date
For 2025 Q3 Consolidated Financial Report Is 2025/11/03

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scinopharm Taiwan (1789 TT)

Board Of Directors Approved The Company'S Consolidated Financial Report Of Q3, 2025

Announcement Of The Expected Board Meeting Date For 2025 Q3 Consolidated Financial Report Is 2025/11/03

Scinopharm 2025 H1 Webcast Investor Conference

Announcement On Behalf Of The Major Subsidiary Scianda (Changshu) Pharmaceuticals, Ltd. For The Dismissal Of Institutional Supervisor

Board Of Directors Approved The Company'S Consolidated Financial Report Of Q2, 2025

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)